SILEX Company Overview, Contact Details & Competitors

Q: What is SILEX's official website and social media links?

SILEX's official website is silex-partners.com. SILEX has social profiles on LinkedIn.

Q: How many employees does SILEX have currently?

SILEX has approximately 142 employees.

Q: What technology does SILEX use?

SILEX's tech stack includes Apache, Atlassian Confluence, DocuSign, Microsoft PowerPoint, InVision.

Q: What is SILEX's NAICS code?

SILEX's NAICS code is 5239 (Other Financial Investment Activities).

Insights

Gathering insights about SILEX…

Similar companies to SILEX

SILEX Tech Stack

SILEX uses 8 technology products and services including Refinitiv, Amazon Web Services, Azure Logic Apps, and more. Explore SILEX's tech stack below.

Refinitiv
Accounting And Finance
Amazon Web Services
Cloud Hosting
Azure Logic Apps
Cloud Infrastructure Computing
Continuous Delivery
Continuous Integration
Font Awesome
Font Scripts
JavaScript
Programming Languages
HSTS
Security
Animate.css
UI Frameworks

Media & News

Silexion Therapeutics to Attend BIO International Convention 2026
Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that Company management, including the Company's Chief Executive Officer, Ilan Hadar, and the Company's Chief Financial Officer, Mirit Horenshtein-Hadar, will attend the 2026 BIO International Convention, taking place on June 22-25 in San Diego, CA.  
Jun 16, 2026 | www.globenewswire.com
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
Trading on split-adjusted basis will begin at market open on May 29, 2026. This adjustment is expected to help Silexion comply with Nasdaq requirements, enhance its market position, and support its progress in developing SIL204. Trading on split-adjusted basis will begin at market open on May 29, 2026. This adjustment is expected to help Silexion comply with Nasdaq requirements, enhance its market position, and support its progress in developing SIL204.
May 26, 2026 | www.globenewswire.com
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer
May 18, 2026 | www.globenewswire.com
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,995,092 of the Company's ordinary shares originally issued in August 2025 and September 2025 having a reduced exercise price of $0.50 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-290074) and an effective resale registration statement on Form S-3 (No. 333-291210). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about May 18, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.
May 15, 2026 | www.globenewswire.com
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following SIL204 treatment in human pancreatic and non-small cell lung cancer cells harboring a KRAS mutation, supporting potential future evaluation alongside anti-PD-1 therapies including pembrolizumab (Keytruda®) Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following SIL204 treatment in human pancreatic and non-small cell lung cancer cells harboring a KRAS mutation, supporting potential future evaluation alongside anti-PD-1 therapies including pembrolizumab (Keytruda®)
May 14, 2026 | www.globenewswire.com
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its European center of excellence Tel Aviv Sourasky Medical Center's Helsinki Ethics Committee approves planned Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, marking an important clinical site activation milestone at a leading Israeli oncology center; Underscores continued regulatory momentum in preparation for trial initiation Grand Cayman, Cayman Islands, May 13, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp.
May 13, 2026 | www.globenewswire.com
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its European center of excellence
May 13, 2026 | www.globenewswire.com

SILEX's Email Address Formats

SILEX uses at least 1 format(s):

SILEX Email Formats	Example	Percentage
First.Last@silex-partners.com	John.Doe@silex-partners.com	98%
First.MiddleLast@silex-partners.com	John.MichaelDoe@silex-partners.com	1%
First.Middle@silex-partners.com	John.Michael@silex-partners.com	1%

Frequently Asked Questions

Where is SILEX's headquarters located?

SILEX's main headquarters is located at 22 Rue de Villereuse Geneva, Geneva 1207 Switzerland. The company has employees across 5 continents, including EuropeNorth AmericaAsia.

What is SILEX's stock symbol?

SILEX is a publicly traded company; the company's stock symbol is SLXN.

What is SILEX's official website and social media links?

SILEX's official website is silex-partners.com and has social profiles on LinkedIn.

What is SILEX's NAICS code?

SILEX's NAICS code is 5239 - Other Financial Investment Activities.

How many employees does SILEX have currently?

As of June 2026, SILEX has approximately 142 employees across 5 continents, including EuropeNorth AmericaAsia. Key team members include Chief Executive Officer & Managing Partner: A. S.Ceo, Partner: P. P.Ceo, Co-Founder At S I L E X: X. L.. Explore SILEX's employee directory with LeadIQ.

What industry does SILEX belong to?

SILEX operates in the Investment Management industry.

What technology does SILEX use?

SILEX's tech stack includes RefinitivAmazon Web ServicesAzure Logic AppsContinuous DeliveryFont AwesomeJavaScriptHSTSAnimate.css.

What is SILEX's email format?

SILEX's email format typically follows the pattern of First.Last@silex-partners.com. Find more SILEX email formats with LeadIQ.

When was SILEX founded?

SILEX was founded in 2016.

Insights

Similar companies to SILEX

NeoPhotonics

VIAVI Solutions

Newport Corporation

IPG Photonics

Lumentum

Fujikura

Coherent

SILEX Tech Stack

Media & News

Silexion Therapeutics to Attend BIO International Convention 2026

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

SILEX's Email Address Formats

Frequently Asked Questions

Where is SILEX's headquarters located?

What is SILEX's stock symbol?

What is SILEX's official website and social media links?

What is SILEX's NAICS code?

How many employees does SILEX have currently?

What industry does SILEX belong to?

What technology does SILEX use?

What is SILEX's email format?

When was SILEX founded?

SILEX

Company Overview

Media & News

Silexion Therapeutics to Attend BIO International Convention 2026

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?